Philippe Gabríel Steg

Also affiliated with Meta (Israel), Sorbonne Paris Cité

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 31 papers. Top paper: “Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes”.

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

New England Journal of Medicine(2009)10.1056/nejmoa0904327

N/A

1.3DataRank · unranked

7040 citations

Richard C. Becker, Andrzej Budaj, Christopher P. Cannon, Håkan Emanuelsson, Claes Held +14 more

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

European Heart Journal(2012)10.1093/eurheartj/ehs215

N/A

1.3DataRank · unranked

6836 citations

Dan Atar, Luigi P. Badano, Carina Blomstrom Lundqvist, Michael A. Borger, Carlo Di Mario +66 more

Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial

Circulation Heart Failure(2023)10.1161/circheartfailure.122.010259

N/A

1.3DataRank · unranked

52 citations

Brian Claggett, Marc A. Pfeffer, Christopher B. Granger, Lars Køber, Eldrin F. Lewis +10 more

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

Journal of the American College of Cardiology(2020)10.1016/j.jacc.2020.04.031

N/A

1.2DataRank · unranked

2923 citations

Mahesh V. Madhavan, David Jiménez, Taylor Chuich, Isaac Dreyfus, Elissa Driggin +41 more

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

Journal of the American Heart Association(2023)10.1161/jaha.122.029216

N/A

1.1DataRank · unranked

40 citations

Philippe Gabríel Steg, Yann Poulouin, Deepak L. Bhatt, Vera Bittner, Rafael Díaz +10 more

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT

Journal of the American Heart Association(2023)10.1161/jaha.121.026756

N/A

0.959DataRank · unranked

25 citations

Deepak L. Bhatt, Michael Miller, Philippe Gabríel Steg, Eliot A. Brinton, Terry A. Jacobson +11 more

Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances

JAMA(2021)10.1001/jama.2021.9941

N/A

0.864DataRank · unranked

317 citations

Peter Gill, Davina Ghersi, Lisa Campbell, Jeremy Sugarman, Richard Emsley +41 more

Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab

European Journal of Preventive Cardiology(2022)10.1093/eurjpc/zwac107

N/A

0.846DataRank · unranked

15 citations

Jennifer McGinniss, Philippe Gabríel Steg, Deepak L. Bhatt, Vera Bittner, Rafael Díaz +12 more

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial

The Lancet Diabetes & Endocrinology(2025)10.1016/s2213-8587(24)00362-0

N/A

0.700DataRank · unranked

31 citations

Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Lawrence A. Leiter, Silvio E. Inzucchi +17 more

Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials

Nature Medicine(2024)10.1038/s41591-024-03188-z

N/A

0.564DataRank · unranked

42 citations

James P. Pirruccello, Giorgio Melloni, Frederick Kamanu, Marc P. Bonaca, Robert P. Giugliano +12 more

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial

European Heart Journal(2024)10.1093/eurheartj/ehad889

N/A

0.510DataRank · unranked

29 citations

Deepak L. Bhatt, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven Ketchum +7 more

Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial

American Heart Journal(2022)10.1016/j.ahj.2022.01.017

N/A

0.505DataRank · unranked

28 citations

Karen P. Alexander, Zhen Huang, Sean M. O’Brien, Bernard Chaitman, Gregg W. Stone +29 more

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

European Heart Journal - Cardiovascular Pharmacotherapy(2024)10.1093/ehjcvp/pvae025

N/A

0.483DataRank · unranked

24 citations

Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Díaz +82 more

Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial

Journal of the American Heart Association(2025)10.1161/jaha.124.038656

N/A

0.450DataRank · unranked

16 citations

Deepak L. Bhatt, Philippe Gabríel Steg, Michael Miller, Eliot A. Brinton, Richard L. Dunbar +8 more

Lipoprotein(a) and Benefit of Antiplatelet Therapy

JACC Advances(2023)10.1016/j.jacadv.2023.100675

N/A

0.416DataRank · unranked

15 citations

Marc P. Bonaca, David A. Morrow, Michael G. Palazzolo, Petr Jarolı́m, Philippe Gabríel Steg +5 more

Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial

The American Journal of Medicine(2022)10.1016/j.amjmed.2022.02.016

N/A

0.401DataRank · unranked

5 citations

Patrícia O. Guimarães, Gregory G. Schwartz, Deepak L. Bhatt, Vera Bittner, Andrzej Budaj +13 more

Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial

Diabetes Care(2025)10.2337/dc24-2110

N/A

0.360DataRank · unranked

10 citations

Michael Szarek, J. Wouter Jukema, Christa M. Cobbaert, Esther Reijnders, Vera Bittner +9 more

External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry

International Journal of Cardiology(2022)10.1016/j.ijcard.2022.10.132

N/A

0.187DataRank · unranked

2 citations

Deepak L. Bhatt, Yedid Elbez, Grégory Ducrocq, Shinya Goto, Sidney C. Smith +15 more

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis

Critical Care Explorations(2023)10.1097/cce.0000000000000997

N/A

0.104DataRank · unranked

1 citations

Garen Manvelian, Alida Coppi, Amy Damask, Michael Cantor, Manuel A. R. Ferreira +35 more

Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61

European Journal of Heart Failure(2023)10.1002/ejhf.3118

N/A

0DataRank · unranked

9 citations

David A. Morrow, Andrea Bellavia, David D. Berg, Deepak L. Bhatt, Petr Jarolı́m +11 more

Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention – Insights from the CHAMPION program

American Heart Journal Plus Cardiology Research and Practice(2021)10.1016/j.ahjo.2021.100043

N/A

0DataRank · unranked

0 citations

Robert A. Harrington, Gregg W. Stone, Philippe Gabríel Steg, C. Michael Gibson, Christian W. Hamm +9 more

Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

Circulation(2023)10.1161/circulationaha.123.064473

N/A

0DataRank · unranked

173 citations

Roxana Mehran, Mitchell W. Krucoff, Usman Baber, Deepak L. Bhatt, Piera Capranzano +36 more

Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors

Journal of the American College of Cardiology(2023)10.1016/j.jacc.2023.06.045

N/A

0DataRank · unranked

91 citations

Stephen T. Vernon, Jason A. Harmer, Michael P. Gray, Clare Arnott, Eric Bachour +60 more

Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics

European Journal of Heart Failure(2021)10.1002/ejhf.2191

N/A

0DataRank · unranked

109 citations

Brian Claggett, Marc A. Pfeffer, Christopher B. Granger, Lars Køber, Eldrin F. Lewis +20 more

Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events

JACC Heart Failure(2023)10.1016/j.jchf.2023.05.026

N/A

0DataRank · unranked

46 citations

Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Lawrence A. Leiter, Darren K. McGuire +17 more

Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease

Circulation Genomic and Precision Medicine(2021)10.1161/circgen.120.003006

N/A

0DataRank · unranked

14 citations

Giorgio Melloni, Yared Gurmu, Marc P. Bonaca, Frederick Kamanu, Carolina Roselli +17 more

Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial

European Heart Journal(2024)10.1093/eurheartj/ehae614

N/A

0DataRank · unranked

26 citations

Danielle Duffy, M. Cecilia Bahit, Gerald Chi, Harvey D. White, Serge Korjian +71 more

Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI

Journal of the American College of Cardiology(2024)10.1016/j.jacc.2024.03.396

N/A

0DataRank · unranked

30 citations

Serge Korjian, M. Cecilia Bahit, Gerald Chi, Danielle Duffy, John H. Alexander +34 more

Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years

Journal of Thrombosis and Haemostasis(2024)10.1016/j.jtha.2024.09.038

N/A

0DataRank · unranked

8 citations

Sam Schulman, John M. Kittelson, Thomas C. Abshire, James F. Casella, Rita Dale +78 more

Time to Clinical Benefit with Sotagliflozin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Insights from the SCORED Randomized Trial

European Journal of Heart Failure(2024)10.1002/ejhf.3240

N/A

0DataRank · unranked

4 citations

Deepak L. Bhatt, Michael Szarek, Lawrence A. Leiter, Christopher P. Cannon, Renato D. Lópes +5 more

External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry

UNC Libraries(2024)10.17615/2cg0-4859

N/A

0DataRank · unranked

0 citations

Philippe Gabríel Steg, Ivo Petrov, Yedid Elbez, Tabassome Simon, Eli I. Lev +16 more